Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications

US10183055B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10183055-B2
Application numberUS-201715401944-A
CountryUS
Kind codeB2
Filing dateJan 9, 2017
Priority dateJul 21, 2014
Publication dateJan 22, 2019
Grant dateJan 22, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/or impairment, pain, and traumatic brain injury.

First claim

Opening claim text (preview).

What is claimed is: 1. A method for providing analgesia to a subject having a. painful condition comprising administering to the subject a therapeutically effective amount of an oligopeptide comprising an amino acid sequence consisting of the formula: A 1 -A 2 -A 3 -A 4 -A 5 -A 6 -A 7 -A 8 (SEQ ID NO: 1) wherein A 1 is selected from the group consisting of aspartic acid, glutamic acid, and glycosylated forms thereof; A 2 is selected from the group consisting of arginine, lysine, and glycosylated forms thereof; A 3 is selected from the group consisting of valine, alanine, isoleucine, leucine, and glycosylated forms thereof; A 4 is selected from the group consisting of tyrosine, phenylalanine, tryptophan, and glycosylated forms thereof; A 5 is selected from the group consisting of isoleucine, valine, alanine, leucine, and glycosylated forms thereof; A 6 is selected from the group consisting of histidine, arginine, lysine, and glycosylated forms thereof; A 7 is serine or a glycosylated form[s] thereof; and A 8 is absent. 2. The method of claim 1 , wherein the painful condition is selected from the group consisting of cancer-induced bone pain caused by either a primary or metastatic tumor, post-surgical pain, post-herpatic neuralgia, fibromyalgia, inflammatory pain, stroke-induced pain, trauma-based neuropathic pain, multiple sclerosis-induced pain, rheumatoid arthritis, and complex regional pain syndrome. 3. The method of claim 1 , wherein the painful condition is cancer-induced bone pain. 4. The method of claim 1 , wherein at least one of A 1 -A 8 is glycosylated with a monosaccharide or disaccharide. 5. The method of claim 4 , wherein at least one of the monosaccharides or disaccharides is selected from the group consisting of glucose, galactose, xylose, fucose, rhamnose, lactose, cellobiose, and melibiose. 6. The method of claim 1 , wherein A 7 is glycosylated. 7. The method of claim 6 , wherein A 7 is glycosylated with a saccharide selected from the group consisting of glucose, galactose, xylose, fucose, rhamnose, lactose, cellobiose, and melibiose. 8. The method of claim 1 , wherein A 7 is terminated with an amino group. 9. The method of claim 7 , wherein A 7 is terminated with an amino group. 10. The method of claim 1 , wherein the oligopeptide is Ang 1-6-Ser(OG1c)-NH 2 SEQ ID NO: 10). 11. The method of claim 1 , wherein the oligopeptide is Ang 1-6-Ser(OLac)-NH 2. 12. A method for providing analgesia to a subject having a painful condition comprising administering to the subject a therapeutically effective amount of an oligopeptide comprising an amino acid sequence consisting of the formula.: A 1 -A 2 -A 3 -A 4 -A 5 -A 6 -A 7 -A 8 (SEQ ID NO:1) wherein A 1 is selected from the group consisting of aspartic acid, glutamic acid, and glycosylated forms thereof; A 2 is selected from the group consisting of arginine, lysine, and glycosylated forms thereof; A 3 is selected from the group consisting of valine, alanine, isoleucine, leucine, and glycosylated forms thereof; A 4 is selected from the group consisting of tyrosine, phenylalanine, tryptophan, and glycosylated forms thereof; A 5 is selected from the group consisting of isoleucine, valine, alanine, leucine, and glycosylated forms thereof; A 6 is selected from the group consisting of histidine, arginine, lysine, and glycosylated forms thereof; A 7 is selected from the group consisting of proline, glycine, and glycosylated forms thereof; and A 8 is serine or a glycosylated form thereof. 13. The method of claim 12 , wherein the painful condition is selected from the group consisting of cancer-induced bone pain caused by either a primary or metastatic tumor, post-surgical pain, post herpatic neuralgia, fibromyalgia, inflammatory pain, stroke-induced pain, trauma-based neuropathic pain, multiple sclerosis-induced pain, rheumatoid arthritis, and complex regional pain syndrome. 14. The method of claim 12 , wherein the painful condition is cancer-induced bone pain. 15. The method of claim 12 , wherein at least one of A 1 -A 8 is glycosylated with a monosaccharide or disaccharide. 16. The method of claim 15 , wherein at least one of the monosaccharides or disaccharides is selected from the group consisting of glucose, galactose, xylose, fucose, rhamnose, lactose, cellobiose, and melibiose. 17. The method of claim 12 , wherein A 8 is glycosylated. 18. The method of claim 17 , wherein A 8 is glycosylated with a saccharide selected from the group consisting of glucose, galactose, xylose, fucose, rhamnose, lactose, cellobiose, and melibiose. 19. The method of claim 12 , wherein A 8 is terminated with an amino group. 20. The method of claim 18 , wherein A 8 is terminated with an amino group. 21. The method of claim 12 , wherein the oligopeptide is selected from the group consisting of Ang 1-7-Ser-NH 2 (SEQ ID NO: 7), Ang 1-7-Ser(OG1c) -NH 2 (SEQ ID NO: 8), and Ang 1-6-Ser(OLac)-NH 2 (SEQ ID NO: 9).

Assignees

Inventors

Classifications

  • the peptide sequence having less than 12 amino acids and not being part of a ring structure · CPC title

  • A61K38/085Primary

    Angiotensins · CPC title

  • Angiotensins: Related peptides · CPC title

  • having 5 to 11 amino acids · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10183055B2 cover?
The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications i…
Who is the assignee on this patent?
Univ Arizona
What technology area does this patent fall under?
Primary CPC classification A61K38/085. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jan 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).